' Important ' New Data on Second-Line HIV Treatment Regimens: The NADIA Study ' Important ' New Data on Second-Line HIV Treatment Regimens: The NADIA Study

For second-line HIV therapy, both dolutegravir and ritonavir-boosted darunavir regimens, plus two nucleoside reverse-transcriptase inhibitors (NRTIs), maintained good viral suppression during 96 weeks follow-up in the NADIA trial.Reuters Health Information

Source: Medscape Medical News Headlines - June 30, 2022 Category: Consumer Health News Tags: HIV/AIDS News Source Type: news